Literature DB >> 7776449

Cytoreductive surgery for stage IV renal cell carcinoma.

R T Bennett1, S E Lerner, H C Taub, J P Dutcher, J Fleischmann.   

Abstract

To facilitate the regression of extra renal disease in response to systemic therapy, cytoreductive surgery has been advocated as step 1 in the treatment of stage IV renal cell carcinoma. To determine the effect of surgery on subsequent clinical course, we reviewed the treatment records of 30 patients with known stage IV carcinoma of the kidney who underwent nephrectomy or additional procedures in preparation for systemic therapy. Of 30 patients only 7 (23%) underwent systemic therapy postoperatively. Progression of the disease, surgical morbidity and mortality were the factors preventing 77% of our patients from continuing with treatment. Since regression of extra renal lesions is the goal of systemic therapy, our data suggest that nephrectomy and most other cytoreductive operations in preparation for systemic therapy are not efficient treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7776449

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

Review 1.  The role of resection for patients with renal carcinoma.

Authors:  R C Flanigan; P M Yonover
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 2.  Treatment of metastatic renal cell carcinoma.

Authors:  Maxine Sun; Giovanni Lughezzani; Paul Perrotte; Pierre I Karakiewicz
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

3.  New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer.

Authors:  Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

Review 4.  Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.

Authors:  E Jason Abel; Christopher G Wood
Journal:  Nat Rev Urol       Date:  2009-06-16       Impact factor: 14.432

5.  Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable?

Authors:  Brian Shuch; Jonathan Said; Jeff C La Rochelle; Ying Zhou; Gang Li; Tobias Klatte; Fairooz F Kabbinaavar; Allan J Pantuck; Arie S Belldegrun
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

Review 6.  Combination of surgery and immunotherapy in metastatic renal cell carcinoma.

Authors:  Gerald H Mickisch; Roland H Mattes
Journal:  World J Urol       Date:  2005-03-25       Impact factor: 4.226

Review 7.  Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.

Authors:  Stephen H Culp
Journal:  Ther Adv Urol       Date:  2015-10

8.  Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma.

Authors:  M C Uygur; A Usubütün; H Ozen; A Ayhan; S Kendi
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

9.  Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Authors:  Che-kai Tsao; Alexander C Small; Max Kates; Erin L Moshier; Juan P Wisnivesky; Benjamin A Gartrell; Guru Sonpavde; James H Godbold; Michael A Palese; Simon J Hall; William K Oh; Matthew D Galsky
Journal:  World J Urol       Date:  2012-12-08       Impact factor: 4.226

10.  Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.

Authors:  Alexander Kutikov; Robert G Uzzo; Aaron Caraway; Carl T Reese; Brian L Egleston; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Yu-Ning Wong; Jay D Raman; Stephen A Boorjian
Journal:  BJU Int       Date:  2009-11-17       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.